Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.53 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423792 | 0.93 | SPPL2A (0.46) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL6098233 | 0.91 | SPPL2A (0.53) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL5403915 | 0.91 | SPPL2A (0.53) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL14216612 | 0.90 | SPPL2A (0.55) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL5863073 | 0.90 | SPPL2A (0.51) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL14189478 | 0.89 | SPPL2A (0.54) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL5863399 | 0.89 | SPPL2A (0.51) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL14113286 | 0.88 | SPPL2A (0.49) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL14113285 | 0.88 | SPPL2A (0.49) | SPPL2AMLNRABCB11LMNACTSD | |
| SCHEMBL14613955 | 0.87 | SPPL2A (0.52) | SPPL2AMLNRABCB11LMNACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-23 | — | — | US | disclosed |
| US-7045518-B2 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040147758-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1052250-B1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | SEARLE & CO (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6667307-B2 | HIV protease | G.D. SEARLE & CO. | 2003-12-23 | — | — | US | disclosed |
| US-20030191166-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | disclosed |
| US-6380188-B1 | FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS PROTEASE | G. D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-0813519-B1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6169085-B1 | A VIRICIDE FOR PREVENTING AND TREATING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, INHIBITING REPLICATION OF A RETROVIRUS AND TREATING AIDS | G. D. SEARLE & COMPANY | 2001-01-02 | — | — | US | disclosed |
| EP-1052250-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2000-11-15 | — | — | EP | disclosed |
| US-5985870-A | TREATING HIV INFECTIONS | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0861249-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | disclosed |
| WO-1996028418-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147758-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | SPPL2A 349/4885MLNR 3628/4885ABCB11 2340/4885 |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | SPPL2A 349/4885MLNR 3628/4885ABCB11 2340/4885 |
| US-20030191166-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | SPPL2A 349/4885MLNR 3628/4885ABCB11 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.